These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24675166)

  • 21. Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome.
    Ozer K; Horsanali MO; Gorgel SN; Horsanali BO; Ozbek E
    Urol Int; 2017; 98(4):466-471. PubMed ID: 27464069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
    Roehrborn CG; Boyle P; Gould AL; Waldstreicher J
    Urology; 1999 Mar; 53(3):581-9. PubMed ID: 10096388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of resistive index of the prostate and bladder sonomorphologic parameters as replacements for urodynamics to predict bladder outlet obstruction in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Garg G; Sankhwar SN; Goel A; Pandey S; Sharma D; Parihar A
    Low Urin Tract Symptoms; 2019 May; 11(3):163-168. PubMed ID: 30793849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Usefulness of the frequency-volume chart over the International Prostate Symptom Score in patients with benign prostatic hyperplasia in view of global polyuria.
    Yoo S; Park J; Cho SY; Cho MC; Jeong H; Son H
    PLoS One; 2018; 13(7):e0197818. PubMed ID: 29995878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
    Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
    BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.
    Canto EI; Singh H; Shariat SF; Lamb DJ; Mikolajczyk SD; Linton HJ; Rittenhouse HG; Kadmon D; Miles BJ; Slawin KM
    Urology; 2004 May; 63(5):905-10; discussion 910-1. PubMed ID: 15134977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of tools for objective evaluation of infravesical obstruction of men with lower urinary tract symptoms.
    Mazzariol O; Reis LO; Palma PR
    Int Braz J Urol; 2019; 45(4):775-781. PubMed ID: 31136110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Appearance of High Endothelial Venule-Like Vessels in Benign Prostatic Hyperplasia is Associated With Lower Urinary tract Symptoms.
    Inamura S; Shinagawa T; Hoshino H; Sakai Y; Imamura Y; Yokoyama O; Kobayashi M
    Prostate; 2017 May; 77(7):794-802. PubMed ID: 28181681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fully automated prostate segmentation on MRI: comparison with manual segmentation methods and specimen volumes.
    Turkbey B; Fotin SV; Huang RJ; Yin Y; Daar D; Aras O; Bernardo M; Garvey BE; Weaver J; Haldankar H; Muradyan N; Merino MJ; Pinto PA; Periaswamy S; Choyke PL
    AJR Am J Roentgenol; 2013 Nov; 201(5):W720-9. PubMed ID: 24147502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia.
    Mochtar CA; Kiemeney LA; van Riemsdijk MM; Barnett GS; Laguna MP; Debruyne FM; de la Rosette JJ
    Eur Urol; 2003 Dec; 44(6):695-700. PubMed ID: 14644122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
    Hwang EC; Jung JH; Borofsky M; Kim MH; Dahm P
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD013143. PubMed ID: 30759311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic alterations in benign prostatic hyperplasia patients.
    Mohamed HM; Aly MS; Hussein TD
    Ger Med Sci; 2017; 15():Doc16. PubMed ID: 29234244
    [No Abstract]   [Full Text] [Related]  

  • 33. Bloodless management of benign prostatic hyperplasia: medical and minimally invasive treatment options.
    Liatsikos E; Kyriazis I; Kallidonis P; Stolzenburg JU
    Aging Male; 2011 Sep; 14(3):141-9. PubMed ID: 21247241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostatic arterial embolization to treat benign prostatic hyperplasia.
    Pisco JM; Pinheiro LC; Bilhim T; Duarte M; Mendes JR; Oliveira AG
    J Vasc Interv Radiol; 2011 Jan; 22(1):11-9; quiz 20. PubMed ID: 21195898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Six-year follow up of silodosin monotherapy for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: What are the factors for continuation or withdrawal?
    Yamanishi T; Kaga K; Fuse M; Shibata C; Kamai T; Uchiyama T
    Int J Urol; 2015 Dec; 22(12):1143-8. PubMed ID: 26310102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urodynamic Features and Significant Predictors of Bladder Outlet Obstruction in Patients With Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Small Prostate Volume.
    Kang M; Kim M; Choo MS; Paick JS; Oh SJ
    Urology; 2016 Mar; 89():96-102. PubMed ID: 26683755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Automated prostate segmentation in whole-body MRI scans for epidemiological studies.
    Habes M; Schiller T; Rosenberg C; Burchardt M; Hoffmann W
    Phys Med Biol; 2013 Sep; 58(17):5899-915. PubMed ID: 23920310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alternatively Activated Macrophages are Associated with Prostate Volume and Lower Urinary Tract Symptoms Severity of Patients with Benign Prostate Hyperplasia.
    Hu W; Liu W; Yu F; Wu Y; Fang X; Hao W
    Clin Lab; 2017 Jul; 63(7):1057-1062. PubMed ID: 28792700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Convective Water Vapor Energy for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia.
    DeLay KJ; McVary KT
    Urol Clin North Am; 2016 Aug; 43(3):371-5. PubMed ID: 27476129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression?
    Pejcic TP; Tulic CDz; Lalic NV; Glisic BD; Ignjatovic SD; Markovic BB; Hadzi-Djokic JB
    Can J Urol; 2013 Apr; 20(2):6707-13. PubMed ID: 23587511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.